---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-042791"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2024-04-09T23:59:59+00:00"
generated_at: "2026-06-04T00:55:10.154425+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ALKS 2680 shows statistically significant wakefulness improvement in NT2 and IH phase 1b

## Summary
- ALKS 2680 improved mean sleep latency vs placebo at all doses in NT2 (5mg: +12 min, p<0.05; 12mg: +19 min, p<0.001; 25mg: +21 min, p<0.001).
- In IH cohort, mean sleep latency improved by 8 min (5mg, p<0.05), 11 min (12mg, p<0.01), and 18 min (25mg, p<0.001).
- No serious AEs or discontinuations; mild transient TEAEs including pollakiuria, insomnia, dizziness at highest dose.
- Phase 2 study in narcolepsy type 2 planned for second half of 2024.

## SEC filing metadata
- accession: 0000950170-24-042791
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2024-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000095017024042791/0000950170-24-042791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000095017024042791/alks-20240409.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-042791
- JSON: https://secwatch.observer/filing/0000950170-24-042791.json
- Plain text: https://secwatch.observer/filing/0000950170-24-042791.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.